EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma.
Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, Einsele H, Goldschmidt H, Knop S, Li C, Mellqvist UH, McFadden I, Oprea C, Ross JA, Talpes M, Hydren J, Ahlstrom J, Kazandjian D, Weinhold N, Zhang R, Stetler-Stevenson M, Marti GE MD, PhD, Devlin SM.
Landgren O, et al. Among authors: zhang r.
Blood. 2024 May 20:blood.2024024371. doi: 10.1182/blood.2024024371. Online ahead of print.
Blood. 2024.
PMID: 38768337